ADC Therapeutics S.A.is a biotechnology company focused on the development of antibody-drug conjugates for the treatment of hematological cancers. Despite its innovative approach, the company faces challenges in capital efficiency. The Return on Invested Capital (ROIC) for ADCT is -54.62%, significantly lower than its Weighted Average Cost of Capital (WACC) of 20.44%. This negative ROIC indicates that ADCT is not generating sufficient returns to cover its cost of capital, which is a critical measure of financial health.
In comparison, Ciena Corporation (CIEN) shows a more favorable financial position with a ROIC of 3.79% against a WACC of 8.87%, resulting in a ROIC to WACC ratio of 0.43. This suggests that Ciena is generating returns that are closer to covering its cost of capital, although not exceeding it. Meanwhile, COMSovereign Holding Corp. (COMS) presents a stark contrast with a ROIC of -694.61% and a WACC of 15.44%, leading to a ROIC to WACC ratio of -44.99. This indicates severe inefficiencies in capital utilization.
Altair Engineering Inc. (ALTR) and ADTRAN Holdings, Inc. (ADTN) also show challenges in capital efficiency. Altair's ROIC is 0.75% with a WACC of 10.57%, resulting in a ROIC to WACC ratio of 0.07. ADTRAN's figures are slightly better, with a ROIC of -8.41% and a WACC of 9.27%, leading to a ROIC to WACC ratio of -0.91. Both companies are not generating returns that exceed their cost of capital, similar to ADCT.
Sanmina Corporation (SANM) stands out with a ROIC of 9.69% and a WACC of 9.20%, resulting in a ROIC to WACC ratio of 1.05. This indicates that Sanmina is effectively generating returns that exceed its cost of capital, making it the most efficient in terms of capital utilization among the listed companies. This efficiency makes Sanmina an attractive option for investors looking for companies with strong capital management.
